Suchergebnisse - "Paton, Nicholas I"

PubPharm (169)

1

Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?

enthalten in: The Journal of infectious diseases | 2024

von Cross, G. | O' Doherty, J. | Chang, C. | +2

2

Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis : proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial

enthalten in: The Journal of infectious diseases | 2024

von Paton, N. | Gurumurthy, M. | Lu, Q. | +110

3

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy : 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)

enthalten in: EClinicalMedicine | 2024

von Paton, N. | Stöhr, W. | Arenas-Pinto, A. | +112

4

Peripheral Neuropathy in Virologically Suppressed People Living with HIV : Evidence from the PIVOT Trial

enthalten in: Viruses | 2023

von Schuldt, A. | Bern, H. | Hart, M. | +10

5

Recent advances in the treatment of tuberculosis

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023

von Motta, I. | Boeree, M. | Chesov, D. | +20

6

Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis : a phase 2b, randomised, open-label, multicentre trial

enthalten in: The Lancet. Infectious diseases | 2023

von Cross, G. | Sari, I. | Kityo, C. | +46

7

Treatment Strategy for Rifampin-Susceptible Tuberculosis. Reply

enthalten in: The New England journal of medicine | 2023

von Paton, N. | Cousins, C. | Suresh, C.

CommentOn: N Engl J Med. 2023 Mar 9;388(10):873-887. - PMID 36808186

8

Impact of sub-optimal HIV viral control on activated T cells

enthalten in: AIDS (London, England) | 2023

von Arrigoni, F. | Spyer, M. | Hunter, P. | +9

9

Treatment Strategy for Rifampin-Susceptible Tuberculosis

enthalten in: The New England journal of medicine | 2023

von Paton, N. | Cousins, C. | Suresh, C. | +119

CommentIn: Ann Intern Med. 2023 Jun;176(6):JC64. - PMID 37276602

10

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) : week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

enthalten in: The lancet. HIV | 2022

von Paton, N. | Musaazi, J. | Kityo, C. | +101

CommentIn: Lancet HIV. 2022 Jun;9(6):e368-e369. - PMID 35460602

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]